Approval · Notice of Compliance 32845 · 2024
SUMATRIPTAN: Notice of Compliance 32845
Issued March 8, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32845
- Date
- March 8, 2024
- Company
- Sivem Pharmaceuticals UlcSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Licensing Agreement Between Two Manufacturers
- Canadian reference product
- IMITREX (Glaxo Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SUMATRIPTAN | 02546027 | Approved |
| SUMATRIPTAN | 02546035 | Marketed |
| SUMATRIPTAN | 02546043 | Marketed |
Medicinal ingredients
- SUMATRIPTAN 25 MG per TAB
- SUMATRIPTAN 50 MG per TAB
- SUMATRIPTAN 100 MG per TAB